Bioliberty Raises $10.2 Million to Build Functional Intelligence Capabilities for Post-Acute Care

Lifepoint Health's Russell Bailey and CVS Health's Dana Prommel Strauss to Bring Additional Healthcare Depth to Bioliberty Board of Directors

Mar. 19, 2026 at 12:25am

Got story updates? Submit your updates here. ›

Bioliberty, a healthtech startup transforming the delivery of physical and occupational therapy, announced that it raised $10.2 million in financing. The funds will enable the company to continue the development and U.S. commercialization of its Lifehub Clinic platform, which incorporates new computer vision and care coordination capabilities, as well as the commercialization of Lifehub Home to facilitate ongoing physical therapy and progress tracking in patient homes. The financing includes a $8.2 million Series A investment led by the Scottish National Investment Bank, alongside participation from existing and new investors. As part of this financing, Russell Bailey, President of Lifepoint Rehabilitation, and Dana Prommel Strauss, Lead Director of Public Policy and Government Affairs at CVS Health, have joined Bioliberty's Board of Directors.

Why it matters

Bioliberty's enhanced capabilities arrive at a critical juncture as physical function and mobility emerge as essential "vital signs" in the transition to value-based care. In value-oriented payment models, objective functional data becomes a prerequisite for protecting provider margins, securing shared savings and improving patient outcomes. By providing actionable, objective measures of mobility, Bioliberty enables clinicians to identify high-risk patients, track recovery trajectories, and make data-driven discharge decisions that ensure both clinical excellence and financial stability.

The details

Since launching its flagship product, Lifehub Clinic, in mid-2025, Bioliberty has seen strong clinical adoption of the solution which uses AI and robotics to monitor functional recovery and augment high-intensity therapy delivery in post-acute care settings. The company's technology now supports patients in several of the largest post-acute care providers in the U.S., including through multicenter partnerships with the third largest rehabilitation provider in the country, and Sheltering Arms Institute. It also continues research and development activities through collaborations with the Abilities Research Center at Mt. Sinai, and the IDEAS Center for Innovation at the U.S. Department of Veterans Affairs' Central Virginia VA Health Care System.

  • Bioliberty raised a $2 million pre-Series A round in mid-2025.
  • Bioliberty launched its flagship product, Lifehub Clinic, in mid-2025.

The players

Bioliberty

A healthtech startup transforming the delivery of physical and occupational therapy.

Russell Bailey

The President of Lifepoint Rehabilitation for Lifepoint Health, a leading provider of rehabilitation services in the U.S. He oversees over 300 hospital-based rehab programs, joint venture and standalone rehab hospitals.

Dana Prommel Strauss

The Lead Director of Public Policy and Government Affairs for CVS Health. After nearly 20 years as a treating therapist and population health leader, she now focuses on healthcare delivery policy as an expert on value-based care, including Medicare, post-acute care, and home-based care.

Scottish National Investment Bank

Scotland's development bank that provides patient (long-term) debt or equity investments to businesses and projects that support the development of a fairer, more sustainable Scottish economy.

Archangels

One of the UK's leading angel investment syndicates, connecting seasoned investors with Scotland's most promising early-stage technology and life science companies.

Got photos? Submit your photos here. ›

What they’re saying

“Our team is pleased with the initial success of Lifehub Clinic in the U.S. market, helping post-acute care providers improve patient outcomes through intelligent therapy delivery and discharge planning that incorporates functional data. We look forward to leveraging the expertise of our expanded Board of Directors to further the impact of this work.”

— Rowan Armstrong, co-founder and chief executive officer at Bioliberty

“Throughout my leadership career, I have evaluated numerous emerging technologies, and over the past year, Bioliberty has significantly stood out. The seamless integration into high-intensity clinical workflows and the generation of actionable data for teams have been remarkable. I've witnessed how the platform enhances clinical outcomes while providing care teams and leaders with the visibility needed to standardize care across an expanding post-acute network. I'm thrilled to support Bioliberty as they continue to scale and deliver exceptional value for providers, ultimately ensuring excellent quality outcomes for patients.”

— Russell Bailey, PT FACHE, President of Lifepoint Rehabilitation

“The acceleration of value-based care and interoperability solutions have created an urgent demand for objective data that delivers actionable insights and predicts patient pathways to reduce the total cost of care. Bioliberty is enhancing physical and occupational therapists hands-on time with patients while capturing the 'missing link' of functional mobility data needed to improve discharge planning and reduce readmissions. These critical insights are what the post-acute space has been waiting for.”

— Dana Prommel Strauss, DPT, Lead Director, Public Policy and Government Affairs, CVS Health

The takeaway

Bioliberty's technology advancements in computer vision, AI-driven assessments, and home-based physical therapy are arriving at a critical time as value-based care models place increasing emphasis on objective functional data to improve patient outcomes and reduce healthcare costs. The addition of industry leaders like Russell Bailey and Dana Prommel Strauss to Bioliberty's board signals the company's potential to transform post-acute care delivery through innovative, data-driven solutions.